Effects of heat-killed *Enterococcus faecalis* T-110 supplementation on gut immunity, gut flora, and intestinal infection in normal aged hamsters

Takio Inatomi^{1*}, Konosuke Otomaru²

¹ Inatomi Animal Hospital 1-1-24, Denenchofu, Ota-ku, Tokyo, 145-0071, Japan

² Joint Faculty of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima,
890-0065, Japan

***Corresponding author:** Takio Inatomi

takato.inatomi@gmail.com

Abstract

Infectious diseases are a threat to elderly people, whose immune systems become depressed with age. Among the various infectious diseases, *Clostridium difficile* infections in particular lead to significant mortality in elderly humans and are a serious problem worldwide, especially because of the increasing infection rates. Probiotics have been proposed as an effective countermeasure against *C. difficile* infection. The aim of this study was to evaluate the effects of heat-killed *Enterococcus faecalis* T-110 on intestinal immunity, intestinal flora, and intestinal infections, especially *C. difficile* infections, in naturally ageing animals, for extrapolation to elderly human subjects. Twenty female hamsters were randomly distributed into two groups. Group 1 was fed a basal diet, and group 2 was fed a basal diet supplemented with heat-killed *E. faecalis* for 7 days. Heat-killed *E. faecalis* T-110 improved gut immunity and microflora, especially *Clostridium perfringens* and *C. difficile*, of the normal aged hamsters. Heat-killed *E. faecalis* T-110 may, therefore, be a countermeasure against age-related immune dysfunction and intestinal infections, especially *C. difficile* infection, in elderly humans. However, further investigation in humans is needed.

Introduction

Infectious diseases are a leading cause of mortality and significant morbidity in elderly adult humans, who are at greater risk than younger populations [1]. Increasing age has been

associated with diminished humoral and cell-mediated immunity against newly encountered pathogens or vaccines [2-6], which suggests the need for countermeasures against age-related immune dysfunction.

Among the many infectious diseases, *Clostridium difficile* infections are a social problem in elderly humans. These bacteria produce a toxin resulting in symptoms ranging from mild diarrhoea to inflammation of the bowel (pseudomembranous colitis), which can cause death. *Clostridium difficile*-associated diarrhoea is a severe form of diarrhoea caused by *C. difficile* in humans. There are three key risk factors associated with the development of this infection: antibiotic use [7], increasing age [8], and hospitalisation [9]. *Clostridium difficile*-associated diarrhoea is responsible for approximately 10%–20% of all cases of antibiotic-associated diarrhoea [10] and can occur up to 8 weeks after antibiotic therapy [11]. With the increasing threat of *C. difficile* infection, probiotics have been proposed as one of the effective countermeasures against *C. difficile* infection [12-14].

Probiotics have been defined as live, microbial, food components that are beneficial for human health. Recently, because they have been shown to exhibit beneficial effects equal to those of live microbes; genetically engineered microbes and nonviable microbes are regarded as probiotics [15,16]. Lactic acid bacteria, one of the most common types of probiotic bacteria, have been reported to exhibit beneficial effects on host homeostasis, including activation of the immune function [17,18]. To date, many heat-killed lactic acid bacteria have been shown to

modulate specific and/or non-specific immune responses in animal models and occasionally in human subjects [19].

Regarding the use of probiotics for infection control, it is important that the probiotics administered are not infectious. *Enterococcus faecalis* T-110 (TOA Pharmaceutical Co. Ltd., Tokyo, Japan), which belongs to the group of lactic acid bacteria, is unlikely to be a causative agent of opportunistic infection [20]. *Enterococcus faecalis* T-110 is approved for medical use and is widely used in Japan, China, and India for the treatment and prevention of infectious diseases. In terms of safety, *E. faecalis* T-110 is considered suitable for treating and preventing infectious diseases.

Several studies have shown that the ageing process affects the gut flora [21-24]. Generally, senescence-accelerated animals are often used to investigate the effects of ageing. However, few studies have shown that the gut flora of senescence-accelerated animals is similar to that of normal, ageing animals. Stephan et al. [25] reported that laboratory mice have a different gut microbiota than free-living mammals and humans, making them unsuitable for the study of gut immunity. *Clostridium difficile* is a bacterium endemic to the intestine of hamsters. Elderly hamsters often suffer from diarrheal infections, especially *C. difficile* infections [26]. These factors suggest that they are the best model of *C. difficile* infections in elderly animals. Challenge tests are generally conducted in bacterial infection tests, but these are considered to be unsuitable as infection models for indigenous intestinal bacteria caused by

immunosuppression due to ageing. Few studies have investigated the effects of safety-guaranteed, heat-killed bacteria on intestinal immunity, gut flora, or intestinal infections in normally aged animals. Therefore, the aim of this study was to evaluate the effects of heat-killed *E. faecalis* T-110 on intestinal immunity, flora, and infections in naturally ageing animals, for prospective extrapolation of such information to studies on elderly humans.

Materials and Methods

Ethical approval

This study was conducted at Inatomi Animal Clinic in Tokyo Prefecture, Japan. It was performed under the fundamental guidelines for the proper conduct of animal experiments and related activities at academic research institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology. It was approved by the Ethics Committee of the Inatomi Animal Clinic (Tokyo, Japan; approval number 2020-001).

Animals, diets, and management

A total of 20 healthy, 547-day-old female hamsters (*Phodopus sungorus*) were purchased from Japan SLC, Inc., Hamamatsu, Japan, and acclimatised for 10 days prior to use in the experiments. These animals were healthy and did not receive any treatments prior to the study. They were randomly divided into two treatment groups (groups 1 and 2) of 10 hamsters each

and housed individually in a cage (27 × 15 × 10 cm) in a 24 h light/dark cycle for 14 days.

Temperature was maintained at 26 ± 1 °C, and a basic diet (Rodent Diet CE-2, CLEA JAPAN,

Tokyo, Japan) and water were provided *ad libitum*.

Group 2 of hamsters received 0.1 ml heat-killed *E. faecalis* T-110 saline suspensions (1.0 ×

10⁷ cfu/ml) daily from days 1 to 7. Heat-killed *E. faecalis* T-110, a commercial product of a

heat-killed and dried cell preparation (TOA Biopharma, Tokyo, Japan), was used. The heat-

killed *E. faecalis* T-110 saline suspensions were prepared, as previously described [27]. The

faeces from individual hamsters was checked daily during this experiment and was categorised

according to a faecal score (0, normal faeces; 1, loose stool; 2, moderate diarrhoea; 3, severe

diarrhoea).

Immunological study

On days 1, 7, and 14, the faeces of all hamsters were also measured for total immunoglobulin

A (IgA) concentration using a commercial enzyme-linked immunosorbent assay (ELISA) kit

(Hamster Immunoglobulin A ELISA Kit, My BioSource, Inc, California, USA). The ELISA

procedure was conducted according to the protocol of the manufacturer.

Microbiological study

The faeces of hamsters were used for the microbiological study. Bacterial genomic DNA from

the samples was extracted using a commercial extraction system (QuickGene 810 and Quick Gene DNA tissue kit; KURABO, Osaka, Japan), as previously described [28]. Quantitative real-time polymerase chain reaction (PCR) analyses of *Bifidobacterium* sp., *Clostridium perfringens*, *Lactobacillus* spp., and *C. difficile* were performed using the Rotor-Gene system 6200 (Qiagen, Tokyo, Japan), as previously described [29]. The primer sequences and PCR conditions for each bacterium are given in Table 1.

Table 1 Primers and thermal cycling profiles in this study

Primers	Sequencing	Annealing Temperature (°C)	Reference
<i>Bifidobacterium</i> sp.-F	5'-GATTCTGGCTCAGGATGAACGC-3'	60 °C	Gueimonde et al. [49]
<i>Bifidobacterium</i> sp.-R	5'-CTGATAGGACGCGACCCCAT-3'	60 °C	Gueimonde et al. [49]
<i>Lactobacillus</i> group-F	5'-AGCAGTAGGGAATCTTCCA-3'	58 °C	Rinttila et al. [50]
<i>Lactobacillus</i> group-R	5'-CACCGCTACACATGGAG-3'	58 °C	Rinttila et al. [50]
<i>Clostridium perfringens</i> -F	5'-CGCATAACGTTGAAAGATGG-3'	60 °C	Wise & Siragusa [51]
<i>Clostridium perfringens</i> -R	5'-CCTTGGTAGGCCGTTACCC-3'	60 °C	Wise & Siragusa [51]
<i>Clostridium difficile</i> -F	5'- TTGAGCGATTACTTCGGTAAAGA- 3'	58 °C	Rinttila et al. [50]
<i>Clostridium difficile</i> -R	5'-CCATCCTGTACTGGCTCACCT-3'	58 °C	Rinttila et al. [50]

F – forward primer, R – reverse primer.

Statistical analysis

Values are presented as means $\pm$ standard errors. The Mann–Whitney U-test was applied to analyse differences between mean values in all parameters. Differences between mean values were considered significant at $P < 0.05$ in all statistical analyses. The Mann–Whitney U-test was performed using EZR software (Saitama Medical Center, Jichi Medical University); EZR is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0) [30]. The significance level was set at $P < 0.05$.

Results

Total number of days of abnormal defaecation

From days 1 to 7, the total number of days in which abnormal faeces were observed improved in group 2 compared with group 1 ($P < 0.05$) (Table 2). In the second week, there was no difference in the total number of days in which abnormal faeces was detected in group 1 and group 2.

Table 2 Total number of days in which abnormal faeces were apparent in hamsters fed a basal diet (group 1) and a 1.0×10^7 cfu/ml supplement of heat-killed *Enterococcus faecalis* (group 2)

	Days 1–7	Days 8–14
--	----------	-----------

Group 1	1.4 ± 0.3^a	1.2 ± 0.2
Group 2	0.3 ± 0.2^b	0.9 ± 0.2

^{a, b} Different letters within columns indicate differences between treatment groups ($P < 0.05$).

Immunological study

Total immunoglobulin A (IgA) concentration of faeces was significantly higher in group 2 than that in group 1 at day 7 (Table 3). At days 1 and 14, no difference in total immunoglobulin A (IgA) concentration was detected between group 1 and group 2.

Table 3 Total immunoglobulin A (IgA) concentration (mg/g) of faeces in hamsters fed a basal diet (group 1) and a 1.0×10^7 cfu/ml supplement of heat-killed *Enterococcus faecalis* (group 2)

	Day 1	Day 7	Day 14
Group 1	2.12 ± 0.09	1.98 ± 0.08^a	2.01 ± 0.12
Group 2	2.08 ± 0.09	2.31 ± 0.08^b	1.99 ± 0.11

^{a, b} Different letters within columns indicate differences between treatment groups ($P < 0.05$).

Microbiological study

On the first day, the numbers of *Bifidobacterium* sp., *C. perfringens*, *Lactobacillus* spp., and

C. difficile in faeces were not significantly different between the two groups (Table 4). On day 7, the number of *C. perfringens* and *C. difficile* in faeces was lower in the group 2. The numbers of *Bifidobacterium* sp. and *Lactobacillus* spp. were not significantly different between the two groups. After day 14, the numbers of *Bifidobacterium* sp., *C. perfringens*, *Lactobacillus* spp., and *C. difficile* was similar in faeces of the two groups.

Discussion

Immunological study

Immunoglobulin A is one of the main defence elements that prevents pathogenic microorganisms from crossing the intestinal epithelial cell barrier and is important in protecting the intestinal mucosa [31, 32]. In the present study, heat-killed *E. faecalis* T-110 increased total immunoglobulin A (IgA) concentration in the faeces (Table 3). Similar effects have been observed in other studies [33-38]. Havenaar and Spanhaak [39] demonstrated that probiotics stimulate the immunity of animals in two ways: 1) flora from the probiotic migrate throughout the gut wall and multiply to a limited extent and 2) antigens released by dead microorganisms are absorbed and stimulate the immune system. The responsible mechanisms remain unclear; however, it has been suggested that heat-killed *E. faecalis* T-110 stimulates gut immunity, consistent with the results of previous studies.

Microbiological study

In this study, heat-killed *E. faecalis* T-110 decreased the number of *C. perfringens* and *C. difficile* in aged hamsters (Table 4). Similar effects have been noted in other studies [40-47]. Considering the increased faecal IgA in the current study, it is likely that heat-killed *E. faecalis* T-110 decreased the number of *C. perfringens* and *C. difficile* by improving gut immunity of ageing animals, consistent with the results of previous studies.

Table 4 Microbiological analyses of faeces (log cells/g) of hamsters fed a basal diet (group 1) and a 1.0×10^7 cfu/ml supplement of heat-killed *Enterococcus faecalis* (group 2)

	Day	Group 1	Group 2
<i>Lactobacillus</i> spp.	1	5.72 ± 0.20	5.62 ± 0.20
	7	5.40 ± 0.16	5.45 ± 0.20
	14	5.62 ± 0.24	5.85 ± 0.23
<i>Bifidobacterium</i> sp.	1	5.35 ± 0.12	5.53 ± 0.21
	7	5.60 ± 0.14	5.82 ± 0.22
	14	5.61 ± 0.14	5.88 ± 0.15
<i>Clostridium perfringens</i>	1	5.83 ± 0.07	5.69 ± 0.11

	7	5.72 ± 0.13^a	4.51 ± 0.13^b
	14	5.47 ± 0.04	5.40 ± 0.09
<i>Clostridium difficile</i>	1	5.34 ± 0.05	5.14 ± 0.10
	7	5.48 ± 0.06^a	4.25 ± 0.09^b
	14	5.62 ± 0.06	5.67 ± 0.06

a, b Different letters within rows indicate differences between treatment groups ($P < 0.05$).

Total number of days of abnormal defaecation

In this study, heat-killed *E. faecalis* T-110 decreased the total number of days of abnormal defaecation. *Clostridium perfringens* and *C. difficile* cause diarrhoea in hamsters [48]. Considering the decreased number of *C. perfringens* and *C. difficile* in the current study, it is likely that heat-killed *E. faecalis* T-110 decreased the total number of days of abnormal defaecation by improving gut immunity in ageing animals.

Conclusions

Administration of heat-killed *E. faecalis* T-110 improved the gut immunity and flora in normal, ageing animals. However, further elucidation of the mechanism underlying improved immunity is needed.

192

193 **Author Contributions**

194 T.I. performed the experiments and drafted the manuscript. K.O. designed the study and
195 supervised the project.

196

197 **Competing Interests**

198 The authors declare no competing interests.

199

200 **Funding**

201 The authors received no specific funding for this work.

202

203 **Data availability**

204 All relevant data are within the paper and its Supporting Information files.

205

References

1. Gavazzi G, Krause KH. Ageing and infection. *Lancet Infect Dis.* 2002;2(11):659–66.
2. Phair J, Kauffman CA, Bjornson A, Adams L, Linnemann C Jr. Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function. *J Lab Clin Med.* 1978;92(5):822–8.
3. Cook JM, Gualde M, Hessel L, Mounier M, Michel JP, Denis F, Ratinaud MH. Alterations in the human immune response to the hepatitis B vaccine among the elderly. *Cell Immunol.* 1987;109(1):89–96.
4. Burns EA, Lum LG, L'Hommedieu G, Goodwin JS. Specific humoral immunity in the elderly: *in vivo* and *in vitro* response to vaccination. *J Gerontol.* 1993;48(6):B231–236.
5. Kolibab K, Smithson SL, Shriner AK, Khuder S, Romero-Steiner S, Carlone GM, Westerink MAJ. Specific humoral immunity in the elderly: *in vivo* and *in vitro* response to vaccination. *Immun. Ageing.* 2005;2:10.
6. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein G, Sambhara S. Challenges for vaccination in the elderly. *Immun. Ageing.* 2007;4:9.
7. Bartlett JG. Narrative review: the new epidemic of *Clostridium difficile*-associated enteric disease. *Ann Intern Med.* 2006;145(10):758–64.
8. Karlström O, Fryklund B, Tullus K, Burman LG. A prospective nationwide study of

225 *Clostridium difficile*–associated diarrhea in Sweden. Clin Infect Dis. 1998;26(1):141–
226 5.

227 9. Wiström J, Norrby SR, Myhre EB, Eriksson S, Granström G, Lagergren L, Englund
228 G, Nord CE, Svenungsson B. Frequency of antibiotic-associated diarrhoea in 2462
229 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother.
230 2001;47(1):43–50.

231 10. Bartlett, JG. Antibiotic-associated diarrhea. N Engl J Med, 2002; 346 (5), 334–339.

232 11. Gerding DN, Olson MM, Peterson LR. *Clostridium difficile*—associated diarrhea and
233 colitis in adults a prospective case-controlled epidemiologic study. Arch Intern Med.
234 1986;146(1):95–100.

235 12. Rodriguez H, Miller JE. Do prophylactic probiotics prevent the incidence of
236 *Clostridium difficile* colitis infection in hospitalized patients? J Okla State Med Assoc.
237 2019;112(1):18–9.

238 13. Sinclair A, Xie X, Saab L, Dendukuri N. Lactobacillus probiotics in the prevention of
239 diarrhea associated with *Clostridium difficile*: a systematic review and Bayesian
240 hierarchical meta-analysis. CMAJ Open. 2016;4(4):E706–E718.

241 14. Lau CS, Chamberlain RS. Probiotics are effective at preventing *Clostridium difficile*-
242 associated diarrhea: a systematic review and meta-analysis. Int J Gen Med.
243 2016;9:27–37.

15. Isolauri E, Kirjavainen PV, Salminen S. Probiotics: a role in the treatment of intestinal infection and inflammation? Gut. 2002;50 (Suppl III):iii54–iii59.
16. Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics—approaching a definition. Am J Clin Nutr. 2001;73(suppl):361S–364S.
17. Alvarez-Olmos MI, Oberhelman RA. Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. Clin Infect Dis. 2001;32:1567–76.
18. Fernandes CF, Shahani KM. Anticarcinogenic and immunological properties of dietary *Lactobacilli*. J Food Prot. 1990;53(8):704–10.
19. Ezendam J, van Loveren H. Probiotics: immunomodulation and evaluation of safety and efficacy. Nutr Rev. 2006;64(1):1–14.
20. Noguchi N, Nakaminami H, Nakase K, Sasatsu M. Characterization of *Enterococcus* strains contained in probiotic products. Biol Pharm Bull. 2011;34(9):1469–73.
21. Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Nikkila J, Monti D, Satokari R, Franceschi C, Brigidi P, De Vos W. Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS One. 2010;5(5): e10667.
22. Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, Stanton C, van Sinderen D, O’Connor M, Harnedy N, O’Connor K, Henry C, O’Mahonyi D, Fitzgerald AP, Shanahan F,

- Twomey C, Hill C, Ross RP, O'Toole PW. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc Natl Acad Sci USA*. 2011;108 (Suppl 1):4586–91.
23. E Biagi, M Candela, S Fairweather-Tait, C Franceschi, P Brigidi. Ageing of the human meta-organism: the microbial counterpart. *Age*. 2012;34:247–67.
24. Mueller S, Saunier K, Hanisch C, Norin E, Alm L, Midtvedt T, Cresci A, Silvi S, Orpianesi C, Verdenelli MC, Clavel T, Koebsnick C, Zunft HJF, Doré J, Blaut M. Differences in fecal microbiota in different European study populations in relation to age, gender, and country: A cross-sectional study. *Appl Environ Microbiol*. 2006;72:1027–33.
25. Rosshart SP, Herz J, Vassallo BG, Hunter A, Wall MK, Badger JH, McCulloch JA, Anastasakis DG, Sarshad AA, Leonardi I, Collins N, Blatter JA, Han S-J, Tamoutounour S, Potapova S, Foster St Claire MB, Yuan W, Sen SK, S Dreier MS, Hild B, Hafner M, Wang D, Iliev ID, Belkaid Y, Trinchieri G, Rehermann B. Laboratory mice born to wild mice have natural microbiota and model human immune responses. *Science*. 2019;365(6452):eaaw4361.
26. Miedel EL, Hankenson FC. Chapter 5 - Biology and Diseases of Hamsters. *American College of Laboratory Animal Medicine*, 2015; p 209–45.
27. Wagner RD, Pierson C, Warner T, Dohnalek M, Hilty M, Balish E. Probiotic effects

of feeding heat-killed *Lactobacillus acidophilus* and *Lactobacillus casei* to *Candida albicans*-colonized immunodeficient mice. J Food Prot. 2000;63(5):638-44.

28. Hayakawa T, Masuda T, Kurosawa D, Takamitsu A. Dietary administration of probiotics to sows and/or their neonates improves the reproductive performance, incidence of post-weaning diarrhea and histopathological parameters in the intestine of weaned piglets. Anim Sci J. 2016;87(12):1501–10.

29. Tsukahara T, Inoue R, Nakayama K, Inatomi T. Inclusion of *Bacillus amyloliquefaciens* strain TOA5001 in the diet of broilers suppresses the symptoms of coccidiosis by modulating intestinal microbiota. Anim Sci J. 2018;89(4):679–87.

30. Kanda Y. Investigation of the freely available easy-to-use software 'EZ' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.

31. Fagarasan S, Honjo T. Intestinal IgA synthesis: regulation of front-line body defences. Nat Rev Immunol. 2003;3(1):63–72.

32. Lyu Y, Wu L, Wang F, Shen X, Lin D. Carotenoid supplementation and retinoic acid in immunoglobulin A regulation of the gut microbiota dysbiosis. Exp Biol Med. 2018;243:613–20.

33. Arai S, Iwabuchi N, Takahashi S, Xiao J, Abe F, Hachimura S. Orally administered heat-killed *Lactobacillus paracasei* MCC1849 enhances antigen-specific IgA secretion and induces follicular helper T cells in mice. PLoS One.

2018;13(6):e0199018.

34. Kikuchi Y, Kunitoh-Asari A, Hayakawa K, Imai S, Kasuya K, Abe K, Adachi Y, Fukudome S, Takahashi Y, Hachimura S. Oral administration of *Lactobacillus plantarum* strain AYA enhances IgA secretion and provides survival protection against influenza virus infection in mice. PLoS One. 2014;9(1):e86416.

35. Ishikawa H, Kutsukake E, Fukui T, Sato I, Shirai T, Kurihara T, Okada N, Danbara H, Toba M, Kohda N, Maeda Y, Matsumoto T. Oral administration of heat-killed *Lactobacillus plantarum* strain b240 protected mice against *Salmonella enterica* Serovar Typhimurium. Biosci Biotechnol Biochem. 2010;74(7):1338–42.

36. Campeotto F, Suau A, Kape NL, Magne F, Viallon V, Ferrari Ls, Waligora-Dupriet A-J, Soulaïnes P, Leroux B, Kalach N, Dupont C, Butel M-J. A fermented formula in pre-term infants: clinical tolerance, gut microbiota, down-regulation of faecal calprotectin and up-regulation of faecal secretory IgA. Br J Nutr. 2011;105:1843–51.

37. Sukegawa S, Ihara Y, Yuge K, Rao S, Oka K, Arakawa F, Fujimura T, Murakami H, Kurazono H, Takahashi M, Morimatsu F. Effects of oral administration of heat-killed *Enterococcus faecium* strain NHRD IHARA in post-weaning piglets. Anim Sci J. 2014;85(4):454–60.

38. Sakai F, Hosoya T, Ono-Ohmachi A, Ukibe K, Ogawa A, Moriya T, Kadooka Y, Shiozaki T, Nakagawa H, Nakayama Y, Miyazaki T. *Lactobacillus gasseri* SBT2055

induces TGF- β Expression in dendritic cells and activates TLR2 signal to produce

IgA in the small intestine. PLoS One. 2014;9(8):e105370.

39. Havenaar R, Spanhaak S. Probiotics from an immunological point of view. Curr Opin Biotechnol. 1994;5(3):320–5.

40. Canducci F, Armuzzi A, Cremonini F, Cammarota G, Bartolozzi F, Pola P, Gasbarrini G, Gasbarrini A. A lyophilized and inactivated culture of *Lactobacillus acidophilus* increases *Helicobacter pylori* eradication rates. Aliment Pharmacol Ther. 2000;14:1625–9.

41. Aiba Y, Ishikawa H, Tokunaga M, Komatsu Y. Anti-*Helicobacter pylori* activity of non-living, heat-killed form of *Lactobacilli* including *Lactobacillus johnsonii* No. 1088. FEMS Microbiol Lett. 2017;364(11).

42. Chauvière G, Coconnier MH, Kerneis S, Darfeuille-Michaud A, Joly B, Servin AL. Competitive exclusion of diarrheagenic *Escherichia coli* (ETEC) from human enterocyte-like Caco-2 cells by heat-killed *Lactobacillus*. FEMS Microbiol Lett. 1992;70(3):213–7.

43. Moyen EN, Bonneville F, Fauchère JL. Modification of intestinal colonization and translocation of *Campylobacter jejuni* by erythromycin and an extract of *Lactobacillus acidophilus* in axenic mice. Ann Inst Pasteur Microbiol. 1985;137A(2):199–207.

44. Chen C-Y, Tsen H-Y, Lin C-L, Lin C-K, Chuang L-T, Chen C-S, Chiang Y C.
Enhancement of the immune response against *Salmonella* infection of mice by heat-killed multispecies combinations of lactic acid bacteria. *J Med Microbiol.* 2013;62(Pt 11):1657–64.
45. Ishikawa H, Kutsukake E, Fukui T, Sato I, Shirai T, Kurihara T, Okada N, Danbara H, Toba M, Kohda N, Maeda Y, Matsumoto T. Oral administration of heat-killed *Lactobacillus plantarum* strain b240 protected mice against *Salmonella enterica* serovar *Typhimurium*. *Biosci Biotechnol Biochem.* 2010;74(7):1338–42.
46. Aiba Y, Ishikawa H, Tokunaga M, Komatsu Y. Anti-*Helicobacter pylori* activity of non-living, heat-killed form of *Lactobacilli* including *Lactobacillus johnsonii* No.1088. *FEMS Microbiol Lett.* 2017;364(11).
47. Schwendicke F, Horb K, Kneist S, Dörfer C, Paris S. Effects of heat-inactivated *Bifidobacterium* BB12 on cariogenicity of *Streptococcus mutans in vitro*. *Arch Oral Biol.* 2014;59(12):1384–90.
48. Miedel EL, Hankenson FC. Chapter 5 - Biology and Diseases of Hamsters. *Laboratory Animal Medicine* (Third Edition). 2015; p 209–45.
49. Gueimonde M, Tölkö S, Korpimäki T, Salminen S. New real-time quantitative PCR procedure for quantification of *Bifidobacteria* in human fecal samples. *Appl Environ Microbiol.* 2014;70(7):4165–9.

50. Rinttilä T, Kassinen A, Malinen E, Krogus L, Palva A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol. 2004;97(6):1166–77.
51. Wise MG, Siragusa GR. Quantitative detection of *Clostridium perfringens* in the broiler fowl gastrointestinal tract by real-time PCR. Appl Environ Microbiol. 2005;71(7):3911–6.